BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,595 | $1,874 | $1,567 | $1,560 |
| - Cash | $0 | $89 | $105 | $105 |
| + Debt | $0 | $739 | $795 | $809 |
| Enterprise Value | $1,595 | $2,525 | $2,256 | $2,264 |
| Revenue | $159 | $163 | $146 | $132 |
| % Growth | -2.4% | 12.2% | 10.6% | – |
| Gross Profit | $157 | $161 | $141 | $125 |
| % Margin | 98.4% | 98.3% | 96.9% | 95.3% |
| EBITDA | $32 | $28 | $25 | -$1 |
| % Margin | 20.2% | 17.4% | 16.9% | -0.9% |
| Net Income | $13 | $5 | $0 | -$27 |
| % Margin | 8.1% | 3.1% | 0% | -20.4% |
| EPS Diluted | 0.059 | 0.02 | 0 | -0.13 |
| % Growth | 193.5% | – | 100% | – |
| Operating Cash Flow | $41 | $41 | -$28 | -$5 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$1 |
| Free Cash Flow | $40 | $41 | -$28 | -$6 |